Skip to main content
. 2017 Jun 1;7(6):1350–1371.

Table 2.

Dicer alteration in drug-resistant cancers

Dicer alteration trend Performed assay Drug resistance Cancer Experimental condition References
Western blot; Quantitative reverse transcriptase PCR Gefitinib Lung cancer Cell culture and human biopsy [125]
Western blot; Quantitative reverse transcriptase PCR Cisplatin Ovarian cancer Cell culture [126]
Immunohistochemical analysis 5-Fluorouracil Oral squamous carcinoma Human biopsy [127]
Western blot Doxorubicin Breast cancer Cell culture [128]
Immunoblot analysis; Quantitative reverse transcriptase PCR Tamoxifen Breast cancer Cell culture [129]
siRNA silencing Cisplatin Breast cancer Cell culture [130]
siRNA silencing Temozolomide Glioblastoma Cell culture [131]
Western blot Cisplatin Cervical cancer Cell culture [132]
* Gel mobility-shift assay Amphiphilic peptide LK-L1C/K6W/L8C Cervical and breast cancer Recombinant human Dicer [133]
*

Functional analysis of Dicer activity.